Novartis Gene Therapies

ZOLGENSMA

View Prices
  1. Home
    2.  / 
  2. J Code
    3.  / ZOLGENSMA – J3399

Manufacturer:

Novartis Gene Therapies

Name:

ZOLGENSMA

HCPCS Code Descriptor:

Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10^15 vector genomes

Category:

J Code

HCPCS:

J3399

NDC(s):

71894-0141-09, 71894-0136-08, 71894-0137-08, 71894-0138-08, 71894-0134-07, 71894-0135-07, 71894-0133-07, 71894-0132-06, 71894-0129-05, 71894-0130-06, 71894-0131-06, 71894-0128-05, 71894-0127-05, 71894-0126-04, 71894-0122-03, 71894-0123-03, 71894-0124-04, 71894-0125-04, 71894-0121-03

Primary Type:

Genetic Disorder

Generic Status:

Single-Source

Route of Administration:

Intravenous

About:

ZOLGENSMA is a Genetic Disorder drug manufactured by Novartis Gene Therapies and administered via the Intravenous route of administration. The J Code: J3399 is aligned to the drug ZOLGENSMA.

View Prices

Access Pricing and More By Registering

Register Now

HCPCS Added Date:

7/1/20

HCPCS Effective Date:

7/1/20

HCPCS Short Description:

Inj onase abepar-xioi treat

Billing and Coding Guide:

https://www.zolgensma-hcp.com/pdf/zolgensma-coding-and-billing-guide.pdf

Patient Assistance:

Not Found